Home/Pipeline/TWYMEEG (Imeglimin)

TWYMEEG (Imeglimin)

Type 2 Diabetes

MarketedCommercialized in Japan

Key Facts

Indication

Type 2 Diabetes

Phase

Marketed

Status

Commercialized in Japan

Company

Poxel

About Poxel

Poxel is a French biotech focused on developing first-in-class treatments for metabolic diseases by targeting mitochondrial bioenergetics. Its strategy leverages two core platforms—direct AMPK activation and optimized thiazolidinediones (TZDs)—to build a pipeline led by mid-stage NASH candidates PXL065 and PXL770. The company has transitioned to a revenue-generating entity through royalties from its partnered drug, Imeglimin, in Japan, but operates under a court-validated financial recovery plan, highlighting significant capital constraints alongside its clinical progress.

View full company profile

Therapeutic Areas

Non-alcoholic Steatohepatitis (NASH)Rare Metabolic Disorders Type 2 Diabetes

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active